Name | SEL120-34A |
Description | SEL120-34A is a selective and ATP-competitive inhibitor of CDK8 with IC50s of 4.4 nM, 10.4 nM and 1070 nM for CDK8/CycC, CDK19/CycC and CDK9/cycT. SEL120-34A possesses antitumor activity. |
In vitro | SEL120-34A shows no obvious inhibition on CDK1, 2, 4, 6, 5, 7. SEL120-34A weakly suppresses CDK9 with an IC50 of 1070 nM. SEL120-34A is active against a panel of AML cell lines including KG-1, SKNO-1, HEL-60, MOLM-16, OciAML-2, MV-4-11, MOLM-6 and OciAML-3 cells with GI50<1 μM[1]. |
In vivo | SEL120-34A (30 mg/kg and 60 mg/kg; p.o.) inhibits the growth of tumors in mice bearing MV4-11 cancer cells. SEL120-34A (30 mg/kg; p.o.) arrests the growth of KG-1-derived tumors[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 4.14 mg/mL (10 mM)
|
Keywords | SEL120 34A | SEL-120-34A | SEL120-34A | SEL12034A |
Inhibitors Related | Ribociclib | Ro-3306 | GSK 3 Inhibitor IX | Rafoxanide | Palbociclib monohydrochloride | CASIN | Palbociclib | GW 441756 | Sodium Oxamate | Abemaciclib | Dinaciclib | Abemaciclib methanesulfonate |
Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |